Key Documents for Shareholders of OSE Immunotherapeutics
Documentation for the Upcoming Meeting
OSE Immunotherapeutics SA, identified by ISIN: FR0012127173 and Mnemo: OSE, has announced that essential documents for the upcoming general meeting are now available for shareholders. This combined general meeting is scheduled for June 25, 2025, at the Drawing House Hotel, Paris, starting at 10:00 a.m.
On May 21, 2025, the convening notice, which includes the agenda and the resolutions, was officially published, providing critical details about how to participate and vote. It will further be disclosed in a legal gazette on June 6, 2025.
Shareholders are encouraged to review these documents, as outlined by Article R. 22-10-23 of the French Commercial Code. For those who cannot attend, provisions are made for electronic requests, allowing registered shareholders to receive copies of pertinent documents. It’s important to note that bearers will need to provide a certificate of participation to exercise this right.
Additionally, shareholders have the option to examine these documents at the company’s registered office in Nantes.
Board's Commitment to Long-Term Value Creation
OSE Immunotherapeutics emphasizes its commitment to a strategy that aims at sustainably creating value for its shareholders. The Board of Directors is dedicated to maintaining good governance and transparency in its operations, ensuring decisions align with long-term objectives that benefit all stakeholders.
As part of ongoing efforts, the Board requests shareholders to reflect on the resolutions being presented. Some resolutions may significantly influence the company's strategic direction and governance structure.
To gain deeper insights into the strategic ambitions and foundational principles guiding the company's direction, shareholders are encouraged to explore additional related information provided concurrently with this announcement.
Addressing Competing Resolutions
The convening brochure outlines various resolutions submitted by a coalition of shareholders who collectively hold around 24% of the voting rights. These shareholders have put forth ten draft resolutions that, if enacted, would substantially alter the composition of the Board of Directors.
The Board articulates that these resolutions could disrupt effective governance and hinder the ongoing implementation of its strategic plan. The Board firmly believes that adopting these proposed changes would jeopardize the company's stability and its growth trajectory.
After a thorough evaluation of the proposed resolutions, the Board advises shareholders to reject these amendments. Comprehensive explanations and voting recommendations regarding the proposed resolutions are available for review in the convening brochure.
Upholding Shareholder Rights and Governance
OSE Immunotherapeutics remains steadfast in its commitment to uphold principles of shareholder democracy. Transparency and equity among shareholders are paramount, ensuring every shareholder’s rights are respected and upheld during the meeting.
The Board has observed the competing resolutions being pushed by the shareholder group. Notably, the shareholders' agreement was only disclosed recently on the French financial authority's website. The company is currently evaluating the implications of these disclosures.
The management commits to conducting the general meeting in a transparent manner, ensuring all shareholder interests are considered. Should the situation deem it necessary, the company reserves the right to implement appropriate actions, including legal avenues.
Precise details regarding participation methods, remote voting, and proxy voting have been laid out according to regulatory requirements.
Continuing the Conversation
For further inquiries and access to the necessary documentation, shareholders can visit the OSE Immunotherapeutics website. This platform hosts all relevant resources regarding the assembly and corporate governance.
About OSE Immunotherapeutics
OSE Immunotherapeutics specializes in the development of innovative products in the fields of immuno-oncology and immuno-inflammation, targeting the unmet needs of patients both now and in the future. Collaborating with prestigious academic institutions and leading biopharmaceutical firms, the company strives to introduce transformative therapies for individuals grappling with severe health challenges. With headquarters located in Nantes and Paris, the company is publicly traded on Euronext, further solidifying its role in the biotechnology landscape.
Frequently Asked Questions
What is the purpose of the upcoming general meeting?
The general meeting aims to discuss important resolutions that impact the company's strategic direction and governance.
Where can shareholders access the preparatory documents?
Preparatory documents are available on the OSE Immunotherapeutics official website for shareholders to review.
How does the Board of Directors ensure transparency?
The Board commits to clear communication and governance practices that uphold shareholder rights and promote fair participation.
What are the implications of the proposed resolutions?
If adopted, the proposed resolutions could lead to significant changes in the Board's structure and governance, potentially affecting the company's strategic continuity.
Who should shareholders contact for more information?
Shareholders can reach out to Fiona Olivier or Sylvie Détry for any inquiries related to the meeting and documentation.
